

PRESS RELEASE

FOR IMMEDIATE RELEASE

**PHARMANIAGA STRENGTHENS CAPITAL MARKET POSITIONING WITH
SHARE CONSOLIDATION APPROVAL**

Key takeaways:

- *Shareholders approved the 5-to-1 share consolidation exercise to strengthen Pharmaniaga's capital market positioning and enhance investor appeal*
- *Expected completion in early June 2026*

PETALING JAYA, 19 MAY 2026 – Pharmaniaga Berhad (Pharmaniaga or The Group) today secured shareholder approval for its proposed share consolidation exercise at the Group's Extraordinary General Meeting (EGM), marking another important step in reinforcing the Group's market positioning and strengthening investor confidence following its successful financial turnaround and return to a stronger footing.

The proposed exercise entails the consolidation of every five existing Pharmaniaga shares into one consolidated share and is aimed at improving share price stability, enhancing trading profile and strengthening the Group's appeal among institutional and long-term investors. The exercise is expected to be completed in early June 2026.

Pharmaniaga Managing Director Dato' Zulkifli Jafar said the Group is now focused on strengthening its capital market profile while executing the next phase of sustainable growth.

Currently, Pharmaniaga has approximately 6.56 billion issued shares. Upon completion of the proposed share consolidation, the number of issued shares will be reduced to approximately 1.31 billion shares. Based on a reference share price of RM0.24, the theoretical adjusted share price would be RM1.20 per consolidated share.

Dato' Zulkifli said the exercise is expected to contribute towards a more stable trading environment by improving overall trading dynamics.

“The exercise is expected to present a stronger reflection of the Company’s financial position and stability. With a healthier balance sheet, sustained financial performance and improved market positioning, the Group believes this will support stronger investor confidence and better position Pharmaniaga alongside more established industry peers,” he added.

The proposed share consolidation is also expected to result in a higher net asset value per share and earnings per share, allowing the Group’s financial metrics to better reflect its improving fundamentals and long-term growth prospects.

Importantly, Dato' Zulkifli emphasised that the exercise will not alter the Group’s overall market capitalisation or the total value of shareholders’ investments, except for minor adjustments arising from fractional entitlements, if any.

He added that the Group remains firmly guided by its Vision ONE30 strategic roadmap, which outlines Pharmaniaga’s ambition to become Malaysia’s most valuable pharmaceutical company by 2030.

“Vision ONE30 provides a clear roadmap for Pharmaniaga to strengthen its core businesses, advance its biopharmaceutical capabilities and enhance operational efficiency, as we work towards achieving RM300 million profit after tax and a market capitalisation of at least RM3 billion by 2030,” he said.

Earlier today, Pharmaniaga also held its 28th Annual General Meeting (AGM), where all resolutions tabled were duly approved by shareholders.



Pharmaniaga Berhad's Board of Directors and management team at the Group's 28th Annual General Meeting and Extraordinary General Meeting

-END-

About Pharmaniaga Berhad

Pharmaniaga is the pharmaceutical arm of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the substantial shareholders of the Company. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products. With a vision to be the premier Malaysian pharmaceutical company, its operations are strengthened by five manufacturing plants, as well as extensive logistics and distribution network in Malaysia and Indonesia. Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical industry.

For more information, please visit <https://pharmaniaga.com/>.

Issued by Imej Jiwa Sdn Bhd on behalf of Pharmaniaga Berhad

For further media inquiries please contact:

Dato' Zuhri Iskandar Kamarzaman (Pharmaniaga)

E-mail: zuhri@pharmaniaga.com

Telephone number: 03-3342 9999 ext. 434

Elizabeth Tan (Imej Jiwa)

E-mail: elizabeth@imejjiwa.com | Mobile: +6012 207 0993